The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | PET-adapted treatment in PMBCL
Eliza A. Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Centre, Melbourne, Australia, discusses using positron emission tomography (PET) scanning in patients with primary mediastinal B-cell lymphoma (PMBCL). PMBCL is a rare form of lymphoma and treatment includes chemotherapy, which typically consists of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), as well as radiotherapy. PET imaging can enable patients to avoid radiotherapy by assessing response to chemotherapy, with PET negative patients not needing radiotherapy. PET imaging in patients with PMBCL was additionally assessed in the IELSG37 trial (NCT01599559), with results yet to be released. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
